{
    "info": {
        "nct_id": "NCT05232916",
        "official_title": "A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)",
        "inclusion_criteria": "* HLA-A*02-positive, unless being enrolled in the third non-HLA-A*02 arm\n* Histologically confirmed diagnosis of HER2/neu positive primary breast cancer for all tumors biopsied (multifocal, multicentric, or synchronous contralateral disease)\n* Completion of both neoadjuvant and adjuvant trastuzumab-based standard of care breast cancer therapy\n* Stage I, II, or III at presentation with pathologic evidence of residual invasive carcinoma in the breast or axillary lymph nodes (residual disease) at surgery following completion of neoadjuvant therapy -OR- Stage III at presentation with pathologic complete response (pCR) at surgery following completion of neoadjuvant therapy\n* The subject can begin study therapy within one year of completion of adjuvant trastuzumab-based therapy and any other standard therapies, but, study therapy can be administered concurrently with endocrine therapy.\n* No clinical evidence of residual or persistent breast cancer per treating physician assessment\n* ECOG 0-2\n* Adequate organ function\n* Negative pregnancy test or evidence of post-menopausal status\n* If of childbearing potential, willing to use a form of highly effective contraception\n* Subject must both reside in and have been treated for their cancer in the country in which the clinical site is located.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
        "exclusion_criteria": "* Stage IV cancer or metastatic breast cancer at any time\n* Inflammatory breast cancer\n* Receiving other investigational agents\n* Receiving chemotherapy\n* Requiring long-term systemic treatment with corticosteroids or other immunosuppressive therapy\n* History of immunodeficiency or active autoimmune disease\n* A history of serious allergic reactions, including anaphylaxis, to human granulocyte-macrophage colony-stimulating factors such as sargramostim, yeast-derived products, or any component of the investigational product\n* Other malignancies except adequately treated in situ carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin\n* Active infection\n* Known HIV infection with a detectable viral load within 6 months of the anticipated start of treatment. Note: Subjects on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Stage I, II, or III at presentation with pathologic evidence of residual invasive carcinoma in the breast or axillary lymph nodes (residual disease) at surgery following completion of neoadjuvant therapy -OR- Stage III at presentation with pathologic complete response (pCR) at surgery following completion of neoadjuvant therapy",
            "criterions": [
                {
                    "exact_snippets": "Stage I, II, or III at presentation",
                    "criterion": "cancer stage at presentation",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "I",
                                "II",
                                "III"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "pathologic evidence of residual invasive carcinoma in the breast or axillary lymph nodes (residual disease) at surgery following completion of neoadjuvant therapy",
                    "criterion": "residual invasive carcinoma after neoadjuvant therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "breast",
                                "axillary lymph nodes"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at surgery following completion of neoadjuvant therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Stage III at presentation",
                    "criterion": "cancer stage at presentation",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "III"
                        }
                    ]
                },
                {
                    "exact_snippets": "pathologic complete response (pCR) at surgery following completion of neoadjuvant therapy",
                    "criterion": "pathologic complete response after neoadjuvant therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at surgery following completion of neoadjuvant therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject must both reside in and have been treated for their cancer in the country in which the clinical site is located.",
            "criterions": [
                {
                    "exact_snippets": "Subject must both reside in ... the country in which the clinical site is located",
                    "criterion": "country of residence",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": "country in which the clinical site is located"
                        }
                    ]
                },
                {
                    "exact_snippets": "have been treated for their cancer in the country in which the clinical site is located",
                    "criterion": "location of cancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": "country in which the clinical site is located"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 100 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 100 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 100,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No clinical evidence of residual or persistent breast cancer per treating physician assessment",
            "criterions": [
                {
                    "exact_snippets": "No clinical evidence of residual or persistent breast cancer",
                    "criterion": "residual or persistent breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "clinical evidence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "per treating physician assessment",
                    "criterion": "treating physician assessment",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": "no clinical evidence of residual or persistent breast cancer"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* HLA-A*02-positive, unless being enrolled in the third non-HLA-A*02 arm",
            "criterions": [
                {
                    "exact_snippets": "HLA-A*02-positive",
                    "criterion": "HLA-A*02 status",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed diagnosis of HER2/neu positive primary breast cancer for all tumors biopsied (multifocal, multicentric, or synchronous contralateral disease)",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed diagnosis of HER2/neu positive primary breast cancer",
                    "criterion": "primary breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "histologically confirmed"
                        },
                        {
                            "requirement_type": "HER2/neu status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "for all tumors biopsied (multifocal, multicentric, or synchronous contralateral disease)",
                    "criterion": "all tumors biopsied",
                    "requirements": [
                        {
                            "requirement_type": "disease sites",
                            "expected_value": [
                                "multifocal",
                                "multicentric",
                                "synchronous contralateral"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The subject can begin study therapy within one year of completion of adjuvant trastuzumab-based therapy and any other standard therapies, but, study therapy can be administered concurrently with endocrine therapy.",
            "criterions": [
                {
                    "exact_snippets": "The subject can begin study therapy within one year of completion of adjuvant trastuzumab-based therapy and any other standard therapies",
                    "criterion": "time since completion of adjuvant trastuzumab-based therapy and any other standard therapies",
                    "requirements": [
                        {
                            "requirement_type": "time since completion",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "study therapy can be administered concurrently with endocrine therapy",
                    "criterion": "concurrent administration of study therapy and endocrine therapy",
                    "requirements": [
                        {
                            "requirement_type": "concurrent administration",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Completion of both neoadjuvant and adjuvant trastuzumab-based standard of care breast cancer therapy",
            "criterions": [
                {
                    "exact_snippets": "Completion of both neoadjuvant and adjuvant trastuzumab-based standard of care breast cancer therapy",
                    "criterion": "trastuzumab-based standard of care breast cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy_phase",
                            "expected_value": [
                                "neoadjuvant",
                                "adjuvant"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Negative pregnancy test or evidence of post-menopausal status",
            "criterions": [
                {
                    "exact_snippets": "Negative pregnancy test",
                    "criterion": "pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of post-menopausal status",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "post-menopausal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ function",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If of childbearing potential, willing to use a form of highly effective contraception",
            "criterions": [
                {
                    "exact_snippets": "If of childbearing potential, willing to use a form of highly effective contraception",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "If of childbearing potential, willing to use a form of highly effective contraception",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use highly effective contraception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG 0-2",
            "criterions": [
                {
                    "exact_snippets": "ECOG 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* A history of serious allergic reactions, including anaphylaxis, to human granulocyte-macrophage colony-stimulating factors such as sargramostim, yeast-derived products, or any component of the investigational product",
            "criterions": [
                {
                    "exact_snippets": "A history of serious allergic reactions, including anaphylaxis, to human granulocyte-macrophage colony-stimulating factors such as sargramostim",
                    "criterion": "serious allergic reactions to human granulocyte-macrophage colony-stimulating factors",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "A history of serious allergic reactions, including anaphylaxis, to ... yeast-derived products",
                    "criterion": "serious allergic reactions to yeast-derived products",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "A history of serious allergic reactions, including anaphylaxis, to ... any component of the investigational product",
                    "criterion": "serious allergic reactions to any component of the investigational product",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active infection",
            "criterions": [
                {
                    "exact_snippets": "Active infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Requiring long-term systemic treatment with corticosteroids or other immunosuppressive therapy",
            "criterions": [
                {
                    "exact_snippets": "Requiring long-term systemic treatment with corticosteroids",
                    "criterion": "systemic corticosteroid treatment",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": "long-term"
                        },
                        {
                            "requirement_type": "necessity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Requiring long-term systemic treatment with...other immunosuppressive therapy",
                    "criterion": "systemic immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": "long-term"
                        },
                        {
                            "requirement_type": "necessity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Stage IV cancer or metastatic breast cancer at any time",
            "criterions": [
                {
                    "exact_snippets": "Stage IV cancer",
                    "criterion": "cancer stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "IV"
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic breast cancer at any time",
                    "criterion": "metastatic breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known HIV infection with a detectable viral load within 6 months of the anticipated start of treatment. Note: Subjects on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.",
            "criterions": [
                {
                    "exact_snippets": "Known HIV infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "detectable viral load within 6 months of the anticipated start of treatment",
                    "criterion": "HIV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible",
                    "criterion": "antiretroviral therapy effectiveness and HIV viral load",
                    "requirements": [
                        {
                            "requirement_type": "antiretroviral therapy effectiveness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "HIV viral load detectability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of immunodeficiency or active autoimmune disease",
            "criterions": [
                {
                    "exact_snippets": "History of immunodeficiency",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other malignancies except adequately treated in situ carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin",
            "criterions": [
                {
                    "exact_snippets": "Other malignancies except adequately treated in situ carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin",
                    "criterion": "other malignancies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "adequately treated in situ carcinoma of the cervix",
                                "basal cell carcinoma of the skin",
                                "squamous cell carcinoma of the skin"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inflammatory breast cancer",
            "criterions": [
                {
                    "exact_snippets": "Inflammatory breast cancer",
                    "criterion": "inflammatory breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receiving chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Receiving chemotherapy",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receiving other investigational agents",
            "criterions": [
                {
                    "exact_snippets": "Receiving other investigational agents",
                    "criterion": "use of other investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}